Anthony Letai
MD PhD
Associate Chief of Hematologic Malignancies
👥Biography 个人简介
Anthony Letai developed BH3 profiling, a functional method to assess cancer cell dependence on specific anti-apoptotic BCL-2 proteins. This technique predicts which tumors will respond to specific BH3-mimetics before treatment begins. His dynamic BH3 profiling approach can rapidly assess therapy-induced apoptotic signaling to predict clinical response. BH3 profiling has been validated across multiple cancer types and is being integrated into clinical trial design.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Anthony Letai 的研究动态
Follow Anthony Letai's research updates
留下邮箱，当我们发布与 Anthony Letai（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment